Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Epidemiology Forecast

Key Highlights

• Immune Complex-MPGN (IC-MPGN) is a subtype of MPGN, which is a kidney disorder caused by the deposition of immune complexes (antigen-antibody) in the glomeruli, leading to activation of the classical complement pathway, which causes inflammation and damage to kidney tissues.
• IC-MPGN, is often secondary to underlying conditions such as infections or autoimmune diseases where immune complexes form in response to chronic antigen exposure, triggering the classical complement pathway, leading to mesangial and endothelial damage. 
• Diagnosis of IC-MPGN involves clinical assessment of symptoms, kidney function tests, and a biopsy to confirm immunoglobulin and complement deposits. Electron microscopy reveals glomerular damage, and further screening identifies secondary causes like infections or autoimmune diseases. In idiopathic cases, genetic and complement analysis may guide treatment.
• In 2023, the United States represented around 50% of the total prevalent cases of IC-MPGN in the 7MM, the highest among them.
• Kidney failure is the most common event associated with the IC-MPGN with about 2,600 Kidney failure cases in the US, followed by Japan with around 570 cases. These numbers are expected to rise during the forecast period.

DelveInsight’s “Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) – Epidemiology Forecast – 2034” report delivers an in-depth understanding of Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The table given below further depicts the key segments provided in the report:

Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Understanding and Diagnosis Algorithm

Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Overview

Immune Complex-MPGN (IC-MPGN) is a kidney disorder primarily characterized by the deposition of immune complexes (antigen-antibody aggregates) within the glomeruli. These deposits activate the classical complement pathway, which triggers an inflammatory response and subsequent damage to renal tissues. MPGN has recently been reclassified into two distinct subtypes based on immunofluorescence findings: IC-MPGN, where both immunoglobulin and complement deposits are present, and C3 glomerulopathy (C3G), which is defined by the predominant deposition of C3.

IC-MPGN is typically caused by a chronic antigen stimulus with the persistence of Circulating Immune Complexes (CICs). The most frequent underlying disorders include chronic infections (hepatitis B/C, streptococcal, and mycoplasma infections), autoimmune diseases (SLE, scleroderma, Sjögren syndrome), while monoclonal gammopathies are exceptional in children. The clinical presentation of MPGN is characterized by a range of signs and symptoms including Hematuria, Proteinuria, Edema, and Nephrotic Syndrome that reflect the impact of the disease on kidney function.

Further details are provided in the report…

Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Diagnosis

To diagnose Membranoproliferative Glomerulonephritis (MPGN), a combination of tests is used to assess kidney function and identify potential causes. A urine test detects protein and blood, common markers of glomerular dysfunction, while a blood test measures levels of protein, cholesterol, and waste products to provide insight into kidney health. The Glomerular Filtration Rate (GFR) test evaluates how effectively the kidneys filter waste, offering crucial information on renal function. A kidney biopsy, which involves obtaining a small tissue sample for microscopic examination, is essential for confirming the diagnosis and classifying MPGN. Since accurate classification is vital for treatment decisions, biopsy analysis must be performed by an expert, often at a research center. Additionally, genetic testing may be conducted to identify inherited factors contributing to MPGN. These tests help establish the diagnosis and inform the appropriate treatment approach for this complex and rare condition.

Further details related to country-based variations are provided in the report…

Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Epidemiology

The IC-MPGN epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases, Gender-specific Cases, and Age-specific Cases of IC-MPGN in the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2021 to 2034. 

• In the 7MM, the total number of diagnosed prevalent cases of IC-MPGN) were ~7000 in 2023.
• In 2023, the diagnosed prevalent cases of IC-MPGN were higher in adults in the United States i.e. ~3,400 in 2023 and it is expected to increase by CAGR of ~2%.
• In 2023, Gender-specific cases of IC-MPGN in the United States were ~2000 and ~1800 for men and women, respectively.
• Among EU4 and the UK, Germany accounted for the highest number of total prevalent cases in 2023, with approximately 600 cases.
• The total diagnosed prevalent cases of IC-MPGN in Japan was expected to grow with CAGR of 1% and reach ~950 by 2034.

Scope of the Report

• The report covers a segment of key events, an executive summary, and a descriptive overview of Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression have been provided.
• A detailed review of current challenges in establishing diagnosis and diagnosis rate is provided.

Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Report Insights

• Patient Population
• Total Diagnosed Prevalent Cases, Gender-specific Cases, and Age-specific Cases of IC-MPGN
• Country-wise Epidemiology Distribution

Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Report Key Strengths

• Eleven-year Forecast
• The 7MM Coverage 
• Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Epidemiology Segmentation

Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Report Assessment

• Epidemiology Segmentation
• Current Diagnostic Practices

FAQs

Epidemiology Insights

• What are the disease risks, burdens, and unmet needs of Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)?
• What is the historical and forecasted Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What is the diagnostic pattern of Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)?
• Which clinical factors will affect Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)?
• Which factors will affect the increase in the diagnosis of Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)?

Reasons to buy

• Insights on disease burden, details regarding diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the change in Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) cases in varying geographies over the coming years.
• A detailed overview of Total Diagnosed Prevalent Cases, Gender-specific Cases, and Age-specific Cases of IC-MPGN is included.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis and insights on the treatment-eligible patient pool.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.